BiotechTube
Home/Investors/Public shareholders via NSE listing

Public shareholders via NSE listing

Biotech Investor · 2 portfolio companies

Portfolio
2
Combined Value
$1511.3B
Focus Areas
11
Top Stage
Commercial

Investment Focus

DiabetesCardiovascularRespiratoryOncologyGastroenterologyPain ManagementDermatologyVaccinesImmunologyAutoimmune DiseasesNephrology

Portfolio Companies

CompanyValuation
Zydus Lifesciences$896.0B
Biocon$615.3B

Frequent Co-Investors

Promoter group (Patel family)1 sharedSerum Institute of India1 shared